Combination of Immunotherapy and Brain Radiotherapy in Metastatic Melanoma: A Retrospective Analysis

Giulia Galli, Stefano Cavalieri, Lorenza Di Guardo, Carolina Cimminiello, Federico Nichetti, Francesca Corti, Monica Alicia Garcia, Brigida Pappalardi, Carlo Fallai, Filippo De Braud, Marco Platania, Michele Del Vecchio

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Up to 40% of patients with metastatic melanoma (MM) develop brain metastases. Radiotherapy (RT) may potentiate the effects of immunotherapy (IO), even on distant sites (abscopal effect). Material and Methods: We retrospectively analyzed all our MM patients treated with IO within 6 months before/after brain RT between 2012 and 2016. Progression-free (PFS) and overall survival (OS) were estimated with the Kaplan-Meier method and compared with those of controls treated with IO during the same period. Results: Thirty-six cases and 25 controls were identified. Among cases, 23 patients received an anti-CTLA4 agent and 13 an anti-PD1 agent. Eighteen cases were treated with stereotactic RT and 18 with whole-brain RT. Median PFS from the beginning of RT was 4 months in first-line and 2 months in second-line treatment. A third of the cases progressed at first evaluation after RT. Median OS from the beginning of RT was 7 months in first-line and 4 months in second-line treatment. Median PFS and OS of each treatment line showed a trend towards inferiority compared with those of controls. Conclusion: Synergism between RT and IO was not observed in our case series. No cases of abscopal effect were seen, and most patients underwent early systemic progression after RT.

Original languageEnglish
Pages (from-to)182-188
Number of pages7
JournalOncology Research and Treatment
Volume42
Issue number4
DOIs
Publication statusPublished - Apr 1 2019

Fingerprint

Immunotherapy
Melanoma
Radiotherapy
Brain
Survival
Therapeutics
Neoplasm Metastasis

Keywords

  • Brain
  • Immunotherapy
  • Melanoma
  • Metastasis
  • Radiotherapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Combination of Immunotherapy and Brain Radiotherapy in Metastatic Melanoma : A Retrospective Analysis. / Galli, Giulia; Cavalieri, Stefano; Di Guardo, Lorenza; Cimminiello, Carolina; Nichetti, Federico; Corti, Francesca; Garcia, Monica Alicia; Pappalardi, Brigida; Fallai, Carlo; De Braud, Filippo; Platania, Marco; Del Vecchio, Michele.

In: Oncology Research and Treatment, Vol. 42, No. 4, 01.04.2019, p. 182-188.

Research output: Contribution to journalArticle

Galli, Giulia ; Cavalieri, Stefano ; Di Guardo, Lorenza ; Cimminiello, Carolina ; Nichetti, Federico ; Corti, Francesca ; Garcia, Monica Alicia ; Pappalardi, Brigida ; Fallai, Carlo ; De Braud, Filippo ; Platania, Marco ; Del Vecchio, Michele. / Combination of Immunotherapy and Brain Radiotherapy in Metastatic Melanoma : A Retrospective Analysis. In: Oncology Research and Treatment. 2019 ; Vol. 42, No. 4. pp. 182-188.
@article{aa96283815dc4641b8e5020af5306ebf,
title = "Combination of Immunotherapy and Brain Radiotherapy in Metastatic Melanoma: A Retrospective Analysis",
abstract = "Up to 40{\%} of patients with metastatic melanoma (MM) develop brain metastases. Radiotherapy (RT) may potentiate the effects of immunotherapy (IO), even on distant sites (abscopal effect). Material and Methods: We retrospectively analyzed all our MM patients treated with IO within 6 months before/after brain RT between 2012 and 2016. Progression-free (PFS) and overall survival (OS) were estimated with the Kaplan-Meier method and compared with those of controls treated with IO during the same period. Results: Thirty-six cases and 25 controls were identified. Among cases, 23 patients received an anti-CTLA4 agent and 13 an anti-PD1 agent. Eighteen cases were treated with stereotactic RT and 18 with whole-brain RT. Median PFS from the beginning of RT was 4 months in first-line and 2 months in second-line treatment. A third of the cases progressed at first evaluation after RT. Median OS from the beginning of RT was 7 months in first-line and 4 months in second-line treatment. Median PFS and OS of each treatment line showed a trend towards inferiority compared with those of controls. Conclusion: Synergism between RT and IO was not observed in our case series. No cases of abscopal effect were seen, and most patients underwent early systemic progression after RT.",
keywords = "Brain, Immunotherapy, Melanoma, Metastasis, Radiotherapy",
author = "Giulia Galli and Stefano Cavalieri and {Di Guardo}, Lorenza and Carolina Cimminiello and Federico Nichetti and Francesca Corti and Garcia, {Monica Alicia} and Brigida Pappalardi and Carlo Fallai and {De Braud}, Filippo and Marco Platania and {Del Vecchio}, Michele",
year = "2019",
month = "4",
day = "1",
doi = "10.1159/000497211",
language = "English",
volume = "42",
pages = "182--188",
journal = "Oncology Research and Treatment",
issn = "2296-5270",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Combination of Immunotherapy and Brain Radiotherapy in Metastatic Melanoma

T2 - A Retrospective Analysis

AU - Galli, Giulia

AU - Cavalieri, Stefano

AU - Di Guardo, Lorenza

AU - Cimminiello, Carolina

AU - Nichetti, Federico

AU - Corti, Francesca

AU - Garcia, Monica Alicia

AU - Pappalardi, Brigida

AU - Fallai, Carlo

AU - De Braud, Filippo

AU - Platania, Marco

AU - Del Vecchio, Michele

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Up to 40% of patients with metastatic melanoma (MM) develop brain metastases. Radiotherapy (RT) may potentiate the effects of immunotherapy (IO), even on distant sites (abscopal effect). Material and Methods: We retrospectively analyzed all our MM patients treated with IO within 6 months before/after brain RT between 2012 and 2016. Progression-free (PFS) and overall survival (OS) were estimated with the Kaplan-Meier method and compared with those of controls treated with IO during the same period. Results: Thirty-six cases and 25 controls were identified. Among cases, 23 patients received an anti-CTLA4 agent and 13 an anti-PD1 agent. Eighteen cases were treated with stereotactic RT and 18 with whole-brain RT. Median PFS from the beginning of RT was 4 months in first-line and 2 months in second-line treatment. A third of the cases progressed at first evaluation after RT. Median OS from the beginning of RT was 7 months in first-line and 4 months in second-line treatment. Median PFS and OS of each treatment line showed a trend towards inferiority compared with those of controls. Conclusion: Synergism between RT and IO was not observed in our case series. No cases of abscopal effect were seen, and most patients underwent early systemic progression after RT.

AB - Up to 40% of patients with metastatic melanoma (MM) develop brain metastases. Radiotherapy (RT) may potentiate the effects of immunotherapy (IO), even on distant sites (abscopal effect). Material and Methods: We retrospectively analyzed all our MM patients treated with IO within 6 months before/after brain RT between 2012 and 2016. Progression-free (PFS) and overall survival (OS) were estimated with the Kaplan-Meier method and compared with those of controls treated with IO during the same period. Results: Thirty-six cases and 25 controls were identified. Among cases, 23 patients received an anti-CTLA4 agent and 13 an anti-PD1 agent. Eighteen cases were treated with stereotactic RT and 18 with whole-brain RT. Median PFS from the beginning of RT was 4 months in first-line and 2 months in second-line treatment. A third of the cases progressed at first evaluation after RT. Median OS from the beginning of RT was 7 months in first-line and 4 months in second-line treatment. Median PFS and OS of each treatment line showed a trend towards inferiority compared with those of controls. Conclusion: Synergism between RT and IO was not observed in our case series. No cases of abscopal effect were seen, and most patients underwent early systemic progression after RT.

KW - Brain

KW - Immunotherapy

KW - Melanoma

KW - Metastasis

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=85062669072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062669072&partnerID=8YFLogxK

U2 - 10.1159/000497211

DO - 10.1159/000497211

M3 - Article

C2 - 30836373

AN - SCOPUS:85062669072

VL - 42

SP - 182

EP - 188

JO - Oncology Research and Treatment

JF - Oncology Research and Treatment

SN - 2296-5270

IS - 4

ER -